OncoMatch/Clinical Trials/NCT07284758
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Is NCT07284758 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cemsidomide and Dexamethasone for multiple myeloma.
Treatment: Cemsidomide · Dexamethasone — This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Must have received: immunomodulatory drug (IKZF1/3 degrader)
must have included an immunomodulatory drug (i.e., IKZF 1/3 degrader)
Must have received: proteasome inhibitor
must have included...a proteasome inhibitor
Must have received: anti-CD38 antibody
must have included...an anti-CD38 antibody
Must have received: T-cell engager
must have included...a T-cell engager (TCE) or chimeric antigen receptor T-cell (CAR-T) therapy
Must have received: CAR-T cell therapy
must have included...a T-cell engager (TCE) or chimeric antigen receptor T-cell (CAR-T) therapy
Cannot have received: (cemsidomide)
Previously treated with cemsidomide
Lab requirements
Blood counts
Kidney function
Liver function
Subjects need to have adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Berenson Cancer Center · West Hollywood, California
- START Midwest · Grand Rapids, Michigan
- START San Antonio · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify